89Zr与177Lu标记阿柏西普在乳腺癌中的诊疗一体化作用
本研究在三阴性乳腺癌(TNBC)小鼠模型中探究89Zr/177Lu标记阿柏西普(Abe)的诊疗一体化作用。89Zr标记Abe的肿瘤摄取在120小时达峰值(SUVmax=3.2±0.64),177Lu标记Abe(11.1 MBq)显著抑制肿瘤生长,16天标准化肿瘤体积约815.66±3.58% vs PBS组3646.52±11.10%(n=5,P<0.01)。作者认为89Zr/177Lu标记Abe可能作为TNBC特异性标志物并具有诊断价值,进一步临床评估和转化对TNBC可能具有重要意义。
要点
- 89Zr标记Abe在TNBC 4T1荷瘤小鼠中肿瘤摄取于120小时达峰值,SUVmax=3.2±0.64。
- 177Lu标记Abe(11.1 MBq)使16天标准化肿瘤体积显著小于PBS组(P<0.01)。
- 成人全身有效剂量估算为0.16 mSv/MBq。
核心结论
- 89Zr/177Lu标记Abe可能是TNBC特异性标志物,具有诊断价值,并为TNBC靶向治疗提供思路。
- 作者认为进一步临床评估和转化对TNBC可能具有重要意义。
研究设计与样本
- 研究为TNBC荷瘤小鼠模型研究,使用89Zr和177Lu经螯合剂偶联标记Abe。
- 采用流式细胞术和细胞免疫荧光染色评估Abe的结合亲和力,并进行序贯PET显像和荧光显像。
- 治疗研究给予177Lu标记Abe后监测肿瘤体积和生存,并进行SPECT显像和生物分布研究。
- 安全性评估包括体重、血细胞测定和主要器官苏木精-伊红(H&E)染色,用OLINDA软件估算剂量。
主要发现
- FITC标记Abe在TNBC 4T1细胞和HUVEC中经流式细胞术和细胞免疫荧光显示与VEGF强结合亲和力。
- 89Zr标记Abe肿瘤摄取于120小时达峰值(SUVmax=3.2±0.64),并在168小时前持续(SUVmax=2.54±0.42)。
- Cy5.5标记Abe组荧光强度超过Cy5.5标记IgG组,提示Cy5.5标记Abe是监测体内肿瘤靶向和定位的可行候选。
- 177Lu标记Abe(11.1 MBq)16天标准化肿瘤体积约815.66±3.58% vs PBS组3646.52±11.10%(n=5,P<0.01)。
- SPECT显像证实肿瘤与正常器官高对比,示177Lu标记Abe选择性肿瘤摄取;血细胞未见明显异常,肝、脾、肾未见明显组织病理学异常。
关键数值与推荐
- 免疫组化染色显示177Lu标记Abe有效抑制肿瘤VEGF和CD31表达,提示血管生成可能被抑制。
- 成人全身有效剂量估算为0.16 mSv/MBq。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Triple-negative breast cancer (TNBC) has a poor prognosis due to the absence of effective therapeutic targets. Vascular endothelial growth factor (VEGF) family are expressed in 30-60% of TNBC, therefore providing potential therapeutic targets for TNBC. Aflibercept (Abe), a humanized recombinant fusion protein specifically bound to VEGF-A, B and placental growth factor (PIGF), has proven to be effective in the treatment in some cancers. Therefore, 89Zr/177Lu-labeled Abe was investigated for its theranostic role in TNBC. METHODS: Abe was radiolabeled with 89Zr and 177Lu via the conjugation of chelators. Flow cytometry and cell immunofluorescent staining were performed to evaluate the binding affinity of Abe. Sequential PET imaging and fluorescent imaging were conducted in TNBC tumor bearing mice following the injection of 89Zr-labeled Abe and Cy5.5-labeled Abe. Treatment study was performed after the administration of 177Lu-labeled Abe. Tumor volume and survival were monitored and SPECT imaging and biodistribution studies were conducted. Safety evaluation was performed including body weight, blood cell measurement, and hematoxylin-eosin (H&E) staining of major organs. Expression of VEGF and CD31 was tested by immunohistochemical staining. Dosimetry was estimated using the OLINDA software. RESULTS: FITC-labeled Abe showed a strong binding affinity to VEGF in TNBC 4T1 cells and HUVECs by flow cytometry and cell immunofluorescence. Tumor uptake of 89Zr-labeled Abe peaked at 120 h (SUVmax = 3.2 ± 0.64) and persisted before 168 h (SUVmax = 2.54 ± 0.42). The fluorescence intensity of the Cy5.5-labeled Abe group surpassed that of the Cy5.5-labeled IgG group, implying that Cy5.5-labeled Abe is a viable candidate monitoring in vivo tumor targeting and localization. 177Lu-labeled Abe (11.1 MBq) served well as the therapeutic component to suppress tumor growth with standardized tumor volume at 16 days, significantly smaller than PBS group (about 815.66 ± 3.58% vs 3646.52 ± 11.10%, n = 5, P < 0.01). Moreover, SPECT images confirmed high contrast between tumors and normal organs, indicating selective tumor uptake of 177Lu-labeled Abe. No discernible abnormalities in blood cells, and no evident histopathological abnormality observed in liver, spleen, and kidney. Immunohistochemical staining showed that 177Lu-labeled Abe effectively inhibited the expression of VEGF and CD31 of tumor, suggesting that angiogenesis may be suppressed by 177Lu-labeled Abe. The whole-body effective dose for an adult human was estimated to be 0.16 mSv/MBq. CONCLUSION: 89Zr/177Lu-labeled Abe could be a TNBC-specific marker with diagnostic value and provide insights into targeted therapy in the treatment of TNBC. Further clinical evaluation and translation may be of high significance for TNBC.
引用
- Yang Q, Chen Z, Qiu Y, et al. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 38135849. doi:10.1007/s00259-023-06575-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。